Fine-Tuning Disease: Driving Proteins for Neurological Health
This activity has been archived and credit is no longer available.
In this presentation, Dr. Huda Zoghbi discusses her work in childhood neurodevelopmental disorders, specifically Rett syndrome. She shares the clinical findings, genetics, protein biomarkers, and possible interventions studied in Rett syndrome. She emphasizes the importance of surgeons making a study of tissues to determine disease pathophysiology.
This Michael E. DeBakey Department of Surgery Grand Rounds session took place on Wednesday, September 28, 2022 at 7:00 a.m.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Surgeons, advanced practice providers, fellows, residents, and medical students in various surgical specialties and subspecialties need to receive regular updates on advances in surgical care and clinical practices. Novel technologies and procedures will be examined as means to improve the diagnosis and treatment of medical conditions requiring surgical intervention. The series aims to expand the knowledge of learners, enhance surgical skills, increase surgical efficiency, disseminate surgical best practices, and improve surgical outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Identify and normalize the levels of disease driving proteins, even in mature brain while discussing the reverse disease features in preclinical models opening the path for clinical trials.
- Understand how gene identification is giving us insight into disease mechanism.
- Learn that the protein that causes Rett syndrome is dosage sensitive and that there are disorders caused either by it’s reduction or increase.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Other Health Professionals
Specialties
- Surgery
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Directors
-
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Term of Approval
September 1, 2022 through September 30, 2024. Original release date: September 1, 2022.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Huda Y. Zoghbi, M.D.
Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Cajal Neuroscience, Inc.; The Column Group; Gladstone Institutes; VIB
- Board Membership: Regeneron Pharmaceuticals, Inc.
Activity Directors
-
Michele Loor, M.D., FACS
Associate Professor
Baylor College of Medicine
Disclosure:
- Consultancy: Vicarious Surgical
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Sukriti Bansal, M.D.
General Surgery Resident
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Scott A. LeMaire, MD, FACS, FAHA, FCCP
Professor and Vice-Chair for Research
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Michele Loor, M.D., FACS
Associate Professor
Baylor College of Medicine
Disclosure:
- Consultancy: Vicarious Surgical
-
Todd Rosengart, M.D., F.A.C.S.
DeBakey-Bard Chair of Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
James W. Suliburk, M.D., FACS
Associate Professor and Chief, Endocrine Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: